

# Mary E Rinella

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7478145/publications.pdf>

Version: 2024-02-01

114  
papers

21,902  
citations

38660

50  
h-index

24915

109  
g-index

118  
all docs

118  
docs citations

118  
times ranked

19064  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2018, 67, 328-357.   | 3.6  | 4,738     |
| 2  | Mechanisms of NAFLD development and therapeutic strategies. <i>Nature Medicine</i> , 2018, 24, 908-922.   | 15.2 | 2,392     |
| 3  | MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. <i>Gastroenterology</i> , 2020, 158, 1999-2014.e1.  | 0.6  | 1,840     |
| 4  | Nonalcoholic Fatty Liver Disease. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 2263.  | 3.8  | 1,810     |
| 5  | Non-alcoholic fatty liver disease. <i>Lancet, The</i> , 2021, 397, 2212-2224.   | 6.3  | 1,035     |
| 6  | Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 394, 2184-2196.  | 6.3  | 818       |
| 7  | Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. <i>Gastroenterology</i> , 2020, 158, 1851-1864.  | 0.6  | 710       |
| 8  | Nonalcoholic fatty liver disease. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15080.   | 18.1 | 612       |
| 9  | The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. <i>Journal of Hepatology</i> , 2004, 40, 47-51.  | 1.8  | 375       |
| 10 | Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet. <i>Journal of Lipid Research</i> , 2008, 49, 1068-1076.  | 2.0  | 364       |
| 11 | NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , 2018, 391, 1174-1185.   | 6.3  | 338       |
| 12 | Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 60-78.  | 8.2  | 330       |
| 13 | American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings. <i>Endocrine Practice</i> , 2022, 28, 528-562. | 1.1  | 323       |
| 14 | Management of NAFLD: a stage-based approach. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 196-205.   | 8.2  | 287       |
| 15 | From NAFLD to MAFLD: Implications of a Premature Change in Terminology. <i>Hepatology</i> , 2021, 73, 1194-1198.  | 3.6  | 266       |
| 16 | Outcomes of Early Liver Transplantation for Patients With Severe Alcoholic Hepatitis. <i>Gastroenterology</i> , 2018, 155, 422-430.e1.  | 0.6  | 263       |
| 17 | Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population-based study. <i>Hepatology</i> , 2015, 62, 773-783.  | 3.6  | 221       |
| 18 | Body mass index as a predictor of hepatic steatosis in living liver donors. <i>Liver Transplantation</i> , 2001, 7, 409-414.  | 1.3  | 219       |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Systematic review with meta-analysis: risk of hepatocellular carcinoma in nonalcoholic steatohepatitis without cirrhosis compared to other liver diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 696-703.   | 1.9 | 211       |
| 20 | Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial. <i>Hepatology</i> , 2020, 72, 58-71.  | 3.6 | 209       |
| 21 | Effects of Belaepectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension. <i>Gastroenterology</i> , 2020, 158, 1334-1345.e5.  | 0.6 | 203       |
| 22 | Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events. <i>Hepatology</i> , 2012, 56, 1741-1750.  | 3.6 | 192       |
| 23 | International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients. <i>Transplantation</i> , 2018, 102, 727-743.   | 0.5 | 178       |
| 24 | The globalization of nonalcoholic fatty liver disease: Prevalence and impact on world health. <i>Hepatology</i> , 2016, 64, 19-22.  | 3.6 | 174       |
| 25 | Nonalcoholic Fatty Liver Disease, Diabetes, Obesity, and Hepatocellular Carcinoma. <i>Clinics in Liver Disease</i> , 2015, 19, 361-379.   | 1.0 | 160       |
| 26 | Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. <i>Annals of Hepatology</i> , 2011, 10, 277-286.  | 0.6 | 153       |
| 27 | The Role of Diet and Nutrient Composition in Nonalcoholic Fatty Liver Disease. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2012, 112, 401-409.   | 0.4 | 141       |
| 28 | Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD. <i>Journal of Hepatology</i> , 2019, 71, 823-833.   | 1.8 | 120       |
| 29 | REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. <i>Contemporary Clinical Trials</i> , 2019, 84, 105803.  | 0.8 | 105       |
| 30 | TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. <i>Gastroenterology</i> , 2021, 161, 1475-1486.  | 0.6 | 101       |
| 31 | Dual-echo, chemical shift gradient-echo magnetic resonance imaging to quantify hepatic steatosis: Implications for living liver donation. <i>Liver Transplantation</i> , 2003, 9, 851-856.  | 1.3 | 94        |
| 32 | Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease. <i>Current Hepatology Reports</i> , 2016, 15, 75-85.   | 0.4 | 87        |
| 33 | NAFLD: Reporting Histologic Findings in Clinical Practice. <i>Hepatology</i> , 2021, 73, 2028-2038.   | 3.6 | 86        |
| 34 | Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis. <i>Gastroenterology</i> , 2020, 159, 1985-1987.e4.  | 0.6 | 83        |
| 35 | A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. <i>Contemporary Clinical Trials</i> , 2020, 88, 105889. | 0.8 | 80        |
| 36 | Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD. <i>Journal of Hepatology</i> , 2022, 76, 1030-1041.   | 1.8 | 74        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD. <i>Hepatology</i> , 2019, 70, 1424-1436.  | 3.6 | 73        |
| 38 | Practice patterns in NAFLD and NASH: real life differs from published guidelines. <i>Therapeutic Advances in Gastroenterology</i> , 2016, 9, 4-12.  | 1.4 | 72        |
| 39 | Longitudinal Association of Non-Alcoholic Fatty Liver Disease With Changes in Myocardial Structure and Function: The CARDIA Study. <i>Journal of the American Heart Association</i> , 2020, 9, e014279. | 1.6 | 72        |
| 40 | The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis. <i>Therapeutic Advances in Gastroenterology</i> , 2011, 4, 249-263.  | 1.4 | 67        |
| 41 | Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 513-526.       | 1.9 | 66        |
| 42 | Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. <i>Journal of Hepatology</i> , 2022, 76, 536-548.                                     | 1.8 | 66        |
| 43 | Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. <i>Annals of Hepatology</i> , 2011, 10, 277-86.   | 0.6 | 66        |
| 44 | Dysregulation of the unfolded protein response in db/db mice with diet-induced steatohepatitis. <i>Hepatology</i> , 2011, 54, 1600-1609.  | 3.6 | 65        |
| 45 | Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum. <i>Hepatology</i> , 2019, 70, 1841-1855.                                      | 3.6 | 64        |
| 46 | Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2019, 70, 735-744.                              | 1.8 | 60        |
| 47 | Impact of renal impairment on cardiovascular disease mortality after liver transplantation for nonalcoholic steatohepatitis cirrhosis. <i>Liver International</i> , 2015, 35, 2575-2583.                | 1.9 | 58        |
| 48 | Preparing for the NASH Epidemic: A Call to Action. <i>Gastroenterology</i> , 2021, 161, 1030-1042.e8.   | 0.6 | 58        |
| 49 | Genetics, diagnostics and therapeutic advances in NAFLD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 65-66.   | 8.2 | 56        |
| 50 | Non-Alcoholic Fatty Liver Disease: Is Bariatric Surgery the Answer?. <i>Clinics in Liver Disease</i> , 2009, 13, 689-710.   | 1.0 | 52        |
| 51 | Testosterone Levels in Pre-Menopausal Women are Associated With Nonalcoholic Fatty Liver Disease in Midlife. <i>American Journal of Gastroenterology</i> , 2017, 112, 755-762.                          | 0.2 | 49        |
| 52 | EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. <i>Journal of Hepatology</i> , 2022, 76, 506-517.   | 1.8 | 49        |
| 53 | Everolimus Is Associated With Less Weight Gain Than Tacrolimus 2 Years After Liver Transplantation. <i>Transplantation</i> , 2017, 101, 2873-2882.  | 0.5 | 46        |
| 54 | The times they are a-changin' (for NAFLD as well). <i>Journal of Hepatology</i> , 2020, 73, 1307-1309.  | 1.8 | 45        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2050-2058.e12.    | 2.4 | 41        |
| 56 | Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 603-616. | 3.7 | 40        |
| 57 | Model to Calculate Harms and Benefits of Early vs Delayed Liver Transplantation for Patients With Alcohol-Associated Hepatitis. <i>Gastroenterology</i> , 2019, 157, 472-480.e5.                              | 0.6 | 39        |
| 58 | GS-06-Positive Results from REGENERATE: A Phase 3 International, Randomized, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for NASH. <i>Journal of Hepatology</i> , 2019, 70, e5.            | 1.8 | 39        |
| 59 | Body mass index trajectories in young adulthood predict nonalcoholic fatty liver disease in middle age: The CARDIA cohort study. <i>Liver International</i> , 2018, 38, 706-714.                              | 1.9 | 38        |
| 60 | A Myriad of Pathways to NASH. <i>Clinics in Liver Disease</i> , 2012, 16, 525-548.  | 1.0 | 37        |
| 61 | Low Awareness of Nonalcoholic Fatty Liver Disease in a Population-Based Cohort Sample: the CARDIA Study. <i>Journal of General Internal Medicine</i> , 2019, 34, 2772-2778.                                   | 1.3 | 37        |
| 62 | Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 274-282.  | 1.8 | 34        |
| 63 | Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis. <i>Digestive Diseases and Sciences</i> , 2016, 61, 1387-1397.  | 1.1 | 32        |
| 64 | Preparing for the NASH Epidemic: A Call to Action. <i>Diabetes Care</i> , 2021, 44, 2162-2172.  | 4.3 | 30        |
| 65 | Nonalcoholic Fatty Liver Disease: Identification and Management of High-Risk Patients. <i>American Journal of Gastroenterology</i> , 2019, 114, 579-590.  | 0.2 | 27        |
| 66 | Patterns of Alcohol Use After Early Liver Transplantation for Alcoholic Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 409-418.e5.  | 2.4 | 27        |
| 67 | Controversies in the Diagnosis and Management of NAFLD and NASH. <i>Gastroenterology and Hepatology</i> , 2014, 10, 219-27.   | 0.2 | 26        |
| 68 | Preparing for the NASH epidemic: A call to action. <i>Metabolism: Clinical and Experimental</i> , 2021, 122, 154822.  | 1.5 | 25        |
| 69 | Non-alcoholic fatty liver disease: Not time for an obituary just yet!. <i>Journal of Hepatology</i> , 2021, 74, 972-974.  | 1.8 | 24        |
| 70 | Sex Hormone-Binding Globulin Levels in Young Men Are Associated With Nonalcoholic Fatty Liver Disease in Midlife. <i>American Journal of Gastroenterology</i> , 2019, 114, 758-763.                           | 0.2 | 23        |
| 71 | STELLAR 3 and STELLAR 4: Lessons from the fall of Icarus. <i>Journal of Hepatology</i> , 2020, 73, 9-11.  | 1.8 | 21        |
| 72 | Real-World Burden of Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1020-1029.e7.  | 2.4 | 21        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | Will the increased prevalence of nonalcoholic steatohepatitis (NASH) in the age of better hepatitis C virus therapy make NASH the deadlier disease?. <i>Hepatology</i> , 2011, 54, 1118-1120.   | 3.6 | 19        |
| 74 | Liraglutide-Induced Autoimmune Hepatitis. <i>JAMA Internal Medicine</i> , 2014, 174, 984.   | 2.6 | 18        |
| 75 | Randomized Controlled Trial of a Leucineâ€Metforminâ€Sildenafil Combination (NSâ€0200) on Weight and Metabolic Parameters. <i>Obesity</i> , 2019, 27, 59-67.                                    | 1.5 | 18        |
| 76 | Medical and Obstetric Complications Among Pregnant Women With Liver Cirrhosis. <i>Obstetrics and Gynecology</i> , 2017, 129, 1118-1123.   | 1.2 | 17        |
| 77 | Atrial fibrillation is highly prevalent yet undertreated in patients with biopsyâ€proven nonalcoholic steatohepatitis. <i>Liver International</i> , 2019, 39, 933-940.                          | 1.9 | 17        |
| 78 | Fatty Liver Disease: Diagnosis and Stratification. <i>Annual Review of Medicine</i> , 2022, 73, 529-544.  | 5.0 | 17        |
| 79 | Hepatic Overexpression of Abcb11 Promotes Hypercholesterolemia and Obesity in Mice. <i>Gastroenterology</i> , 2011, 141, 1404-1411.e2.  | 0.6 | 16        |
| 80 | Intensive Management of Hepatic Failure. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2006, 27, 241-261.   | 0.8 | 14        |
| 81 | Factors Impacting Survival in Those Transplanted for NASH Cirrhosis: Data From the NailNASH Consortium. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 445-455.e2.                 | 2.4 | 13        |
| 82 | Liver biopsy in living donors. <i>Liver Transplantation</i> , 2002, 8, 1123-1125.   | 1.3 | 12        |
| 83 | Interpretation and Management of Hepatic Abnormalities in Pregnancy. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 1392-1398.   | 2.4 | 12        |
| 84 | Resting and Exercise Energy Metabolism After Liver Transplantation for Nonalcoholic Steatohepatitis. <i>Transplantation Direct</i> , 2017, 3, e188.   | 0.8 | 12        |
| 85 | Twentyâ€fiveâ€year trajectories of insulin resistance and pancreatic Î²â€cell response and diabetes risk in nonalcoholic fatty liver disease. <i>Liver International</i> , 2018, 38, 2069-2081. | 1.9 | 11        |
| 86 | A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 234-243.               | 1.9 | 11        |
| 87 | Liver Transplantation for Nonalcoholic Steatohepatitis: Pathophysiology of Recurrence and Clinical Challenges. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3413-3430.                    | 1.1 | 10        |
| 88 | Liver biopsy in the real worldâ€reporting, expert concordance and correlation with a pragmatic clinical diagnosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1472-1480.       | 1.9 | 10        |
| 89 | Amelioration of hepatic inflammation in a mouse model of NASH using a dithiocarbamate derivative. <i>Hepatology International</i> , 2013, 7, 600-609.   | 1.9 | 9         |
| 90 | Fundal variceal bleeding after correction of portal hypertension in patients with cirrhosis. <i>Gastrointestinal Endoscopy</i> , 2003, 58, 122-7.   | 0.5 | 8         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 91  | Moderate Exercise for Nonalcoholic Fatty Liver Disease. <i>JAMA Internal Medicine</i> , 2016, 176, 1083.  | 2.6 | 7         |
| 92  | OTU-14â€¦Positive results from REGENERATE: a phase 3 international, randomized, placebo-controlled study evaluating obeticholic acid treatment for NASH. , 2019, , .  |     | 7         |
| 93  | Preparing for the NASH epidemic: A call to action. <i>Obesity</i> , 2021, 29, 1401-1412.  | 1.5 | 7         |
| 94  | NAFLD and Cardiovascular Disease: Can the Real Association Be Determined?. <i>Current Hepatology Reports</i> , 2014, 13, 130-141.   | 0.4 | 6         |
| 95  | Editorial: Age and Non-Invasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease: Time to Adjust the Clock?. <i>American Journal of Gastroenterology</i> , 2017, 112, 752-754.                       | 0.2 | 6         |
| 96  | Range of Normal Serum Aminotransferase Levels in Liver Transplant Recipients. <i>Transplantation Proceedings</i> , 2019, 51, 1895-1901.   | 0.3 | 6         |
| 97  | Screening for nonalcoholic fatty liver disease in patients with atherosclerotic coronary disease?â€”In principle yes, in practice not yet. <i>Hepatology</i> , 2016, 63, 688-690.   | 3.6 | 4         |
| 98  | Editorial: sarcopenia in liver transplantationâ€”our weakest patients may need the strongest push. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1100-1101.   | 1.9 | 4         |
| 99  | Utility of Metabolomic Biomarkers to Identify Nonalcoholic Fatty Liver Disease in Liver Transplant Recipients. <i>Transplantation Direct</i> , 2021, 7, e784.   | 0.8 | 4         |
| 100 | Nonalcoholic steatohepatitis medical patient journey from the perspective of hepatologists, gastroenterologists and patients: a cross-sectional survey. <i>BMC Gastroenterology</i> , 2022, 22, .                         | 0.8 | 4         |
| 101 | The â€œdoseâ€•of exercise and its effects beyond weight loss. <i>Hepatology</i> , 2015, 61, 1115-1117.  | 3.6 | 3         |
| 102 | Authors' Response. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2013, 113, 211-212.   | 0.4 | 1         |
| 103 | Pregnancy Outcomes Among Women With Liver Cirrhosis [8OP]. <i>Obstetrics and Gynecology</i> , 2017, 129, 3S-3S.   | 1.2 | 1         |
| 104 | 938â€¦Positive Results From REGENERATE: A Phase 3 International, Randomized, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for NASH. <i>American Journal of Gastroenterology</i> , 2019, 114, S546-S546. | 0.2 | 1         |
| 105 | Thanks to CLD for Small Favors: Reduced CVD Risk in Patients Awaiting Liver Transplantation. <i>Digestive Diseases and Sciences</i> , 2021, 66, 7-9.  | 1.1 | 1         |
| 106 | Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. , 2018, 68, 349.   |     | 1         |
| 107 | Drug-induced Liver Injury Associated with the Glucagon-like Peptide 1 (GLP-1) Agonist Liraglutide. <i>American Journal of Gastroenterology</i> , 2013, 108, S335-S336.  | 0.2 | 1         |
| 108 | The Management of Pregnancy in Patients with Advanced Liver Disease Before and After Liver Transplantation. <i>Current Hepatology Reports</i> , 2016, 15, 36-43.  | 0.4 | 0         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 109 | PS-206-Patterns and predictors of alcohol use after early liver transplant for alcoholic hepatitis. Journal of Hepatology, 2019, 70, e137.   | 1.8 | 0         |
| 110 | Obesity-specific health-related quality of life in patients with non-alcoholic steatohepatitis: results from the regenerate study. Journal of Hepatology, 2020, 73, S439.          | 1.8 | 0         |
| 111 | O26â€¦Obeticholic acid improves experimental noninvasive markers of nonalcoholic steatohepatitis and advanced fibrosis: results from regenerate. , 2021, , .                       |     | 0         |
| 112 | P213â€¦Obeticholic acid improves hepatic fibroinflammation assessed by multiparametric MRI: interim results of the regenerate trial. , 2021, , .                                   |     | 0         |
| 113 | An algorithm for the management of non-alcoholic fatty liver disease in primary care. Gastroenterology & Hepatology (Bartlesville, Okla ), 2021, 12, 114-122.                      | 0.0 | 0         |
| 114 | Editorial: global liver fat accumulation and global healthâ€™ towards a sustainable development goal. Authors' reply. Alimentary Pharmacology and Therapeutics, 2022, 55, 489-490. | 1.9 | 0         |